Danaher Reports Revenue Increases of 17% in 2016
Operational improvements at Pall contributed to the overall growth in the Danaher life-sciences sector.
In Danaher’s life-sciences sector, reported revenue was up 6% and core revenue grew 4% during the fourth quarter of 2016. Reported operating profit margin increased to 16.8%, and reported revenue for 2016 was up 17% from 2015.
Danaher executives said operational improvements seen at Pall were a growth driver for the company. Growth in the single-use business at Pall, however, was offset by declines in its process technologies business. Nonetheless, the company managed to release 35 new products in 2016, which the team said got to market 25% faster than products in 2015.
The Danaher team also mentioned that 2016 brought the release of the SCIEX X500B mass spectrometer for the characterization of biologics and the close of the acquisition of Phenomenex, a chromatography consumables business.
Source: Seeking Alpha
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
